Monopar Therapeutics Inc. – NASDAQ:MNPR
Founder-led company
Monopar Therapeutics stock price today
$33.51
+8.97
+36.61%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Monopar Therapeutics stock price monthly change
+3346.68%
month
Monopar Therapeutics stock price quarterly change
+3346.68%
quarter
Monopar Therapeutics stock price yearly change
+6365.47%
year
Monopar Therapeutics key metrics
Market Cap | 136.27M |
Enterprise value | 7.97M |
P/E | -1.74 |
EV/Sales | N/A |
EV/EBITDA | -0.50 |
Price/Sales | N/A |
Price/Book | 1.60 |
PEG ratio | 0.12 |
EPS | -0.52 |
Revenue | N/A |
EBITDA | -8.02M |
Income | -7.60M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMonopar Therapeutics stock price history
Monopar Therapeutics stock forecast
Monopar Therapeutics financial statements
Average Price Target
$29.5
Potential downside: -11.96%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -2.19M | |
|---|---|---|---|
| Sep 2023 | 0 | -1.95M | |
| Dec 2023 | 0 | -1.81M | |
| Mar 2024 | 0 | -1.64M |
| Jun 2023 | 10338604 | 2.50M | 24.2% |
|---|---|---|---|
| Sep 2023 | 8593132 | 1.98M | 23.06% |
| Dec 2023 | 7345159 | 1.75M | 23.93% |
| Mar 2024 | 8912296 | 1.43M | 16.1% |
| Jun 2023 | -2.10M | 2.95M | 641.17K |
|---|---|---|---|
| Sep 2023 | -1.93M | -13.05K | 246.70K |
| Dec 2023 | -1.54M | 2.97M | 334.54K |
| Mar 2024 | -1.65M | -983.30K | 3.18M |
Monopar Therapeutics alternative data
| Aug 2023 | 11 |
|---|---|
| Sep 2023 | 11 |
| Oct 2023 | 11 |
| Nov 2023 | 11 |
| Dec 2023 | 11 |
| Jan 2024 | 11 |
| Feb 2024 | 11 |
| Apr 2024 | 11 |
| May 2024 | 9 |
| Jun 2024 | 9 |
| Jul 2024 | 9 |
Monopar Therapeutics other data
0.26%
-1.23%
of MNPR is owned by hedge funds
33.00K
-155.03K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 36000 | 0 |
| Jun 2024 | 92508 | 0 |
| Oct 2024 | 1550 | 0 |
| Insider | Compensation |
|---|---|
Dr. Chandler D. Robinson M.B.A., M.Sc., MBA, M.D., MSc (1984) Co-Founder, Chief Executive Officer, Pres & Director | $602,890 |
| Dr. Andrew P. Mazar (1962) Executive Vice President of R&D, Chief Scientific Officer and Director | $479,010 |
Ms. Kim R. Tsuchimoto CPA (1963) Chief Financial Officer, Sec. & Treasurer | $273,280 |
-
What's the price of Monopar Therapeutics stock today?
One share of Monopar Therapeutics stock can currently be purchased for approximately $33.51.
-
When is Monopar Therapeutics's next earnings date?
Unfortunately, Monopar Therapeutics's (MNPR) next earnings date is currently unknown.
-
Does Monopar Therapeutics pay dividends?
No, Monopar Therapeutics does not pay dividends.
-
How much money does Monopar Therapeutics make?
Monopar Therapeutics has a market capitalization of 136.27M.
-
What is Monopar Therapeutics's stock symbol?
Monopar Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "MNPR".
-
What is Monopar Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Monopar Therapeutics?
Shares of Monopar Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Monopar Therapeutics's key executives?
Monopar Therapeutics's management team includes the following people:
- Dr. Chandler D. Robinson M.B.A., M.Sc., MBA, M.D., MSc Co-Founder, Chief Executive Officer, Pres & Director(age: 41, pay: $602,890)
- Dr. Andrew P. Mazar Executive Vice President of R&D, Chief Scientific Officer and Director(age: 63, pay: $479,010)
- Ms. Kim R. Tsuchimoto CPA Chief Financial Officer, Sec. & Treasurer(age: 62, pay: $273,280)
-
Is Monopar Therapeutics founder-led company?
Yes, Monopar Therapeutics is a company led by its founder Dr. Chandler D. Robinson M.B.A., M.Sc., MBA, M.D., MSc.
-
How many employees does Monopar Therapeutics have?
As Jul 2024, Monopar Therapeutics employs 9 workers, which is 18% less then previous quarter.
-
When Monopar Therapeutics went public?
Monopar Therapeutics Inc. is publicly traded company for more then 5 years since IPO on 19 Dec 2019.
-
What is Monopar Therapeutics's official website?
The official website for Monopar Therapeutics is monopartx.com.
-
Where are Monopar Therapeutics's headquarters?
Monopar Therapeutics is headquartered at 1000 Skokie Boulevard, Wilmette, IL.
-
How can i contact Monopar Therapeutics?
Monopar Therapeutics's mailing address is 1000 Skokie Boulevard, Wilmette, IL and company can be reached via phone at +84 73880349.
-
What is Monopar Therapeutics stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Monopar Therapeutics in the last 12 months, the avarage price target is $29.5. The average price target represents a -11.96% change from the last price of $33.51.
Monopar Therapeutics company profile:
Monopar Therapeutics Inc.
monopartx.comExchange:
NASDAQ
Full time employees:
9
Industry:
Biotechnology
Sector:
Healthcare
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
1000 Skokie Boulevard
Wilmette, IL 60091
Wilmette, IL 60091
CIK: 0001645469
ISIN: US61023L1089
CUSIP: 61023L108
